Alpharadin Data Updated for the Treatment of Men with Advanced Prostate Cancer that has Spread to Bone
Algeta announced that updated data from the phase III trial, ALSYMPCA, for its investigational drug Alpharadin (radium-223 dichloride). The data confirmed the overall survival of men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases [...]
Dr. S. Meyers Posts a Video About Intermittent vs. Continuous Hormone Therapy for Men with Prostate Cancer and Bone Metastasis
On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer [...]
Cancer Care Changes Financial Assistance Requirements
Cancer Care has announced two changes in their financial assistance program procedures. These changes take effect immediately: 1- Applications for assistance will not be accepted unless the applicant has spoken to a Cancer Care representative [...]
From ASCO: Liver Metastases And Its Prognostic Significance In Men With Metastatic Prostate Cancer
According to data presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract # 4655) the presences of liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer [...]
Towards A Biomarker To Predict Survival in Advanced Prostate Cancer
According to the results of a study published in the Journal of Clinical Oncology a bone scan index (BSI) can assess response to treatment and predict survival in metastatic hormone-refractory prostate cancer. Men who have [...]
My Current Personal Take on Intermittent Hormone Therapy for Prostate Cancer
On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer [...]